Buoyant Crinetics readies paltusotine NDA in acromegaly

19 March 2024
crinetics-pharma-large

Crinetics Pharmaceuticals (Nasdaq: CRNX), a biopharma focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, was trading 14% higher by lunchtime Tuesday.

This followed the Californian company’s presentation of positive top-line results from PATHFNDR-2, the second of two Phase III studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.

"Our team is actively preparing for a potential 2025 launch"PATHFNDR-2 was a randomized, double-blind, placebo-controlled 24-week treatment period, followed by an optional open-label extension study, evaluating paltusotine in 111 participants with acromegaly who were not pharmacologically treated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical